跳至主要内容
临床试验/NCT02812290
NCT02812290招募中不适用

Multi-Centric Observational Study to Analyze the Diagnostic Molecular Features in the Clinical Setting of Lung Allograft Biopsies

University of Alberta20 个研究点 分布在 6 个国家目标入组 700 人开始时间: 2016年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
700
试验地点
20
主要终点
Report the molecular scores (probability) of lung transplant disease in a reference set of 600 transbronchial biopsies.

研究概览

简要总结

Objective: To evaluate the potential impact of molecular phenotyping of transbronchial biopsies in lung transplant recipients with allograft dysfunction, and the potential for developing a safer endobronchial mucosal biopsy format.

详细描述

The current standard for biopsy-based diagnoses of dysfunction of lung transplants is the International Society of Heart and Lung Transplantation (ISHLT) classification applied to transbronchial biopsies, which represents an arbitrary international consensus. Recent data-driven approaches using molecular and conventional technologies indicate that this system produces frequently incorrect diagnoses with potential harm to patients due to inappropriate treatment. especially in relationship to the correct diagnosis of chronic lung allograft dysfunction is a pressing need. To address this unmet need and improve diagnostics in the area of organ transplantation, the Alberta Transplant Applied Genomics Centre (ATAGC, University of Alberta) has developed a new diagnostic system - the Molecular Microscope® Diagnostic System (MMDx) that interprets biopsies in terms of their molecular phenotype. The MMDx, developed first in kidney transplant biopsies with thoroughly established phenotypes, will now be adapted to lung transplant transbronchial biopsies (TBBs). Microarray analysis of lung allograft biopsy specimens will be compared to conventional allograft phenotyping, including clinical, physiologic, radiographic and histological assessment. The present study will use the MMDx™ system to assess and report TBBs, and validate and refine this system in 300 unselected prospectively collected lung TBBs. A subset of the study will examine the third bifurcation mucosal endobronchial biopsies (3BMBs) paired with TBBs from 50 patients to see if the safer 3BMBs can substitute for the TBB to be used by MMDx™. Due to a considerable interest and support from participating Centers, the study is further extended and collected 1032 TBBs and 602 3BMBs from 849 patients. This this is the extension of the INTERLUNG study - INTERLUNGEX.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All lung transplant recipients undergoing a biopsy as determined by their surgeon or physician.

排除标准

  • Patients who declined participation or unable to give informed consent.

结局指标

主要结局

Report the molecular scores (probability) of lung transplant disease in a reference set of 600 transbronchial biopsies.

时间窗: two years

Molecular classifier predicts antibody mediated and T cell mediated rejection, and chronic allograft dysfunction.

Report the molecular diagnoses of the MMDx-TBB system

时间窗: two years

Compare MMDx readings to standard-of-care TBB histology and clinical diagnosis of CLAD.

次要结局

  • Report the molecular diagnoses of the MMDx-3BMB system(two years)
  • Report the molecular scores (probability) of lung transplant disease in a reference set of 600 mucosal endobronchial biopsies.(two years)
  • Report the molecular changes over time in medically indicated follow-up biopsies(two years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Philip Halloran

Distinguished Professor

University of Alberta

研究点 (20)

Loading locations...

相似试验

Diagnostic and Therapeutic Applications of... | 临床试验